Kazan medical journalKazan medical journalКазанский медицинский журнал0368-48142587-9359Eco-Vector63293910.17816/KMJ632939Theoretical and clinical medicineТеоретическая и клиническая медицинаResearch ArticleDifferential expression of the SLC34A2 gene in different histological subtypes of ovarian carcinomasДифференциальная экспрессия гена SLC34A2 в различных гистологических подтипах карцином яичникаhttps://orcid.org/0000-0002-6242-603757217131524AAH-9907-20195157-4348NurgalievaAlsina K.НургалиеваАлсина Камиловна
Russian Federation

Junior Researcher, “Biomarker” Research Laborat, Institute of Fundamental Medicine and Biology

мл. науч. сотр., Научно-исследовательская лаборатория «Биомаркёр», Институт фундаментальной медицины и биологии

alsina.nurgalieva@yandex.ruhttps://orcid.org/0000-0002-5082-98836890-8393FetisovTimur I.ФетисовТимур Игоревич
Russian Federation

Cand. Sci. (Biol.), Researcher, Depart. of Chemical Carcinogenesis

канд. биол. наук, науч. сотр., отдел химического канцерогенеза

timkatryam@yandex.ruhttps://orcid.org/0000-0001-8474-81954314-7701KuzinKonstantin A.КузинКонстантин Александрович
Russian Federation

Junior Researcher, Depart. of Chemical Carcinogenesis

мл. науч. сотр., отд. химического канцерогенеза

kuzin_konstantin@mail.ruhttps://orcid.org/0000-0001-8049-20495759-7475ShakirovaElmira Zh.ШакироваЭльмира Жамилевна
Russian Federation

MD, Cand. Sci. (Med.), Oncologist, Depart. of oncology No. 7

канд. мед. наук, врач-онколог, онкологическое отд. №7

shakirovaej@mail.ruhttps://orcid.org/0000-0002-2547-284323994253900L-8766-20157952-5280KiyamovaRamziya G.КиямоваРамзия Галлямовна
Russian Federation

Dr. Sci. (Biol.), Prof., Head of Depart., Depart. of Biochemistry, Biotechnology and Pharmacology, Head, “Biomarker” Research Laboratory, Institute of Fundamental Medicine and Biology

д-р биол. наук, проф., зав. каф., каф. биохимии, биотехнологии и фармакологии, зав., научно-исследовательская лаборатория «Биомаркёр», Институт фундаментальной медицины и биологии

kiyamova@mail.ruKazan (Volga Region) Federal UniversityКазанский (Приволжский) федеральный университетNational Medical Research Center of Oncology named after N.N. BlokhinНациональный медицинский исследовательский центр онкологии им. Н.Н. БлохинаRepublican Clinical Oncology DispensaryРеспубликанский клинический онкологический диспансер181120242711202410568959053105202414082024Copyright ©; 2024, Eco-VectorCopyright ©; 2024, Эко-Вектор2024Eco-VectorЭко-Векторhttps://kazanmedjournal.ru/kazanmedj/article/view/632939

BACKGROUND: Patients with ovarian carcinoma exhibit varying degrees of sensitivity to chemotherapy. Consequently, enhancing the effectiveness of treatment requires a comprehensive evaluation of tumor characteristics, including the histological subtype.

AIM: To identify novel molecular markers of ovarian cancer by analyzing the expression of candidate genes, namely, BAX, SLC34A2, MUC16, CD300A, and XKR8, in ovarian carcinomas of different histological subtypes.

MATERIAL AND METHODS: Real-time polymerase chain reaction was used to analyze BAX, SLC34A2, MUC16, CD300A, and XKR8 gene expressions in 33 carcinomas, considering histological subtypes. Tumor samples from patients with ovarian carcinoma were obtained from the Blokhin National Medical Research Center of Oncology (Moscow) and Republican Clinical Oncological Dispensary (Kazan). The samples were divided into three groups according to histological subtype: high-grade (n = 16) or low-grade (n = 6) serous ovarian carcinomas, endometrioid ovarian carcinomas (n = 8), and mucinous ovarian carcinomas (n = 3). Further analysis was performed using microarray data from the Gene Expression Omnibus database to determine the expression levels of selected candidate genes in various ovarian carcinoma histological subtypes of ovarian carcinomas. The dataset included 4 samples of normal ovaries and 95 samples of ovarian carcinomas of different histological subtypes, including serous (n = 41), endometrioid (n = 37), and mucinous (n = 13) subtypes. Statistical data analysis was conducted using Prism software. Nonparametric Dunn’s test was employed to compare gene expression among patient groups.

RESULTS: Low-grade serous ovarian carcinomas demonstrated increased SLC34A2 gene expression (p = 0.0257) compared with mucinous ovarian carcinomas. Additionally, bioinformatic analysis revealed increased SLC34A2 gene expression in serous (p = 0.0023) and endometrioid (p = 0.0355) ovarian carcinomas compared with normal ovarian tissues.

CONCLUSION: The SLC34A2 gene may be used as a molecular marker to differentiate histological subtypes of ovarian cancer and therapeutic target for low-grade serous ovarian carcinoma.

Актуальность. Больные карциномой яичника проявляют разную чувствительность к химиотерапии, поэтому для повышения эффективности лечения необходимо учитывать особенности опухоли каждой пациентки, включая гистологический подтип.

Цель. Поиск новых молекулярных маркёров рака яичника путём анализа экспрессии генов-кандидатов, включая BAX, SLC34A2, MUC16, CD300A и XKR8, в карциномах яичника разных гистологических подтипов.

Материал и методы. Анализ экспрессии генов BAX, SLC34A2, MUC16, CD300A и XKR8 в 33 карциномах с учётом гистологических подтипов проводили с помощью полимеразной цепной реакции в режиме реального времени. Образцы опухолей пациенток с карциномой яичника были получены из НМИЦ онкологии им. Н.Н. Блохина (Москва) и Республиканского клинического онкологического диспансера (Казань) и распределены на группы по гистологическим подтипам: серозные высокой (n=16) и низкой (n=6) степени злокачественности, эндометриоидные (n=8) и муцинозные (n=3). Дополнительный анализ был осуществлён с использованием данных микрочипов из открытой базы данных Gene Expression Omnibus для определения экспрессии отобранных генов-кандидатов в карциномах яичника разных гистологических подтипов. Набор данных включал 4 образца нормального яичника и 95 образцов карцином яичника различных гистологических подтипов: серозных (n=41), эндометриоидных (n=37), муцинозных (n=13). Статистический анализ данных выполнен с использованием программного обеспечения Prism. Для сравнения экспрессии генов в нескольких группах пациенток применяли непараметрический тест Данна.

Результаты. Выявлено повышение уровня экспрессии гена SLC34A2 в серозных карциномах низкой степени злокачественности (p=0,0257) по сравнению с муцинозными карциномами. С помощью биоинформатического анализа мы выявили повышенную экспрессию гена SLC34A2 в серозных (p=0,0023) и эндометриоидных карциномах яичника (p=0,0355) по сравнению с нормальными тканями яичника.

Вывод. Ген SLC34A2 можно рассматривать в качестве потенциального молекулярного маркёра для дифференциальной диагностики гистологических подтипов рака яичника и мишени для терапии пациенток с серозной карциномой яичника низкой степени злокачественности.

ovarian cancermolecular markershistological subtypesрак яичникамолекулярные маркёрыгистологические подтипыРоссийский научный фондRussian Science Foundation23-15-00456Arora T, Mullangi S, Vadakekut ES, Lekkala MR. Epithelial ovarian cancer. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567760/ Accessed: Mar 9, 2024.Arora T., Mullangi S., Vadakekut E.S., Lekkala M.R. Epithelial ovarian cancer. Treasure Island (FL): StatPearls Publishing, 2024. Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK567760/ Дата обращения: 09.03.2024.Li H, Li J, Gao W, Zhen C, Feng L. Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining. J Ovarian Res. 2020;13(1):27. doi: 10.1186/s13048-020-00627-6Li H., Li J., Gao W., et al. Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining // J Ovarian Res. 2020. Vol. 13, N. 1. P. 27. doi: 10.1186/s13048-020-00627-6Elyashiv O, Aleohin N, Migdan Z, Leytes S, Peled O, Tal O. The poor prognosis of acquired secondary platinum resistance in ovarian cancer patients. Cancers (Basel). 2024;16(3):641. doi: 10.3390/cancers16030641Elyashiv O., Aleohin N., Migdan Z., et al. The poor prognosis of acquired secondary platinum resistance in ovarian cancer patients // Cancers (Basel). 2024. Vol. 16, N. 3. P. 641. doi: 10.3390/cancers16030641Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428. doi: 10.1056/NEJMoa1911361Ray-Coquard I., Leary A., Pignata S., et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer // N Engl J Med. 2019. Vol. 381, N. 25. P. 2416–2428. doi: 10.1056/NEJMoa1911361Farahani H, Boschman J, Farnell D, Darbandsari A, Zhang A, Ahmadvand P, Jones SJM, Huntsman D, Köbel M, Gilks CB, Singh N, Bashashati A. Deep learning-based histotype diagnosis of ovarian carcinoma whole-slide pathology images. Mod Pathol. 2022;35(12):1983–1990. doi: 10.1038/s41379-022-01146-zFarahani H., Boschman J., Farnell D., et al. Deep learning-based histotype diagnosis of ovarian carcinoma whole-slide pathology images // Mod Pathol. 2022. Vol. 35, N. 12. P. 1983–1990. doi: 10.1038/s41379-022-01146-zVan Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. Endocr Relat Cancer. 2018;25(5):R303–R318. doi: 10.1530/ERC-17-0336Van Zyl B., Tang D., Bowden N.A. Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment // Endocr Relat Cancer. 2018. Vol. 25, N. 5. P. R303–R318. doi: 10.1530/ERC-17-0336Varghese A, Lele S. Rare ovarian tumors. In: S Lele, editor. Ovarian cancer. Brisbane (AU): Exon Publications; 2022. doi: 10.36255/exon-publications-ovarian-cancer-rare-ovarian-tumorsVarghese A., Lele S. Rare ovarian tumors. In: Lele S., editor. Ovarian cancer. Brisbane (AU): Exon Publications, 2022. doi: 10.36255/exon-publications-ovarian-cancer-rare-ovarian-tumorsMatulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061. doi: 10.1038/nrdp.2016.61Matulonis U.A., Sood A.K., Fallowfield L., et al. Ovarian cancer // Nat Rev Dis Primers. 2016. Vol. 2. P. 16061. doi: 10.1038/nrdp.2016.61Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS. Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study. Cancers (Basel). 2022;14(9):2230. doi: 10.3390/cancers14092230Huang J., Chan W.C., Ngai C.H., et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study // Cancers (Basel). 2022. Vol. 14, N. 9. P. 2230. doi: 10.3390/cancers14092230Saani I, Raj N, Sood R, Ansari S, Mandviwala HA, Sanchez E, Boussios S. Clinical challenges in the management of malignant ovarian germ cell tumours. Int J Environ Res Public Health. 2023;20(12):6089. doi: 10.3390/ijerph20126089Saani I., Raj N., Sood R., et al. Clinical challenges in the management of malignant ovarian germ cell tumours // Int J Environ Res Public Health. 2023. Vol. 20, N. 12. P. 6089. doi: 10.3390/ijerph20126089Maioru OV, Radoi VE, Coman MC, Hotinceanu IA, Dan A, Eftenoiu AE, Burtavel LM, Bohiltea LC, Severin EM. Developments in genetics: Better management of ovarian cancer patients. Int J Mol Sci. 2023;24(21):15987. doi: 10.3390/ijms242115987Maioru O.V., Radoi V.E., Coman M.C., et al. Developments in genetics: Better management of ovarian cancer patients // Int J Mol Sci. 2023. Vol. 24, N. 21. P. 15987. doi: 10.3390/ijms242115987Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. EJC Suppl. 2020;15:1–15. doi: 10.1016/j.ejcsup.2020.02.001Romero I., Leskelä S., Mies B.P., et al. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications // EJC Suppl. 2020. Vol. 15. P. 1–15. doi: 10.1016/j.ejcsup.2020.02.001Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137–1154. doi: 10.1158/2159-8290.CD-15-0714Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D’Andrea A.D. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer // Cancer Discov. 2015. Vol. 5, N. 11. P. 1137–1154. doi: 10.1158/2159-8290.CD-15-0714Vendrell JA, Ban IO, Solassol I, Audran P, Cabello-Aguilar S, Topart D, Lindet-Bourgeois C, Colombo PE, Legouffe E, D'Hondt V, Fabbro M, Solassol J. Differential sensitivity of germline and somatic BRCA variants to PARP inhibitor in high-grade serous ovarian cancer. Int J Mol Sci. 2023;24(18):14181. doi: 10.3390/ijms241814181Vendrell J.A., Ban I.O., Solassol I., et al. Differential sensitivity of germline and somatic BRCA variants to PARP inhibitor in high-grade serous ovarian cancer // Int J Mol Sci. 2023. Vol. 24, N. 18. P. 14181. doi: 10.3390/ijms241814181Wang Y, Liu L, Yu Y. Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment. Heliyon. 2023;9(8):e19221. doi: 10.1016/j.heliyon.2023.e19221Wang Y., Liu L., Yu Y. Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment // Heliyon. 2023. Vol. 9, N. 8. P. e19221. doi: 10.1016/j.heliyon.2023.e19221Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: A case series. Int J Gynecol Cancer. 2022;32(8):1017–1024. doi: 10.1136/ijgc-2022-003430Sia T.Y., Manning-Geist B., Gordhandas S., et al. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: A case series // Int J Gynecol Cancer. 2022. Vol. 32, N. 8. P. 1017–1024. doi: 10.1136/ijgc-2022-003430Johnson RL, Laios A, Jackson D, Nugent D, Orsi NM, Theophilou G, Thangavelu A, de Jong D. The uncertain benefit of adjuvant chemotherapy in advanced low-grade serous ovarian cancer and the pivotal role of surgical cytoreduction. J Clin Med. 2021;10(24):5927. doi: 10.3390/jcm10245927Johnson R.L., Laios A., Jackson D., et al. The uncertain benefit of adjuvant chemotherapy in advanced low-grade serous ovarian cancer and the pivotal role of surgical cytoreduction // J Clin Med. 2021. Vol. 10, N. 24. P. 5927. doi: 10.3390/jcm10245927Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 2008;5(12):e232. doi: 10.1371/journal.pmed.0050232Köbel M., Kalloger S.E., Boyd N., et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies // PLoS Med. 2008. Vol. 5, N. 12. P. e232. doi: 10.1371/journal.pmed.0050232Assem H, Rambau PF, Lee S, Ogilvie T, Sienko A, Kelemen LE, Köbel M. High-grade endometrioid carcinoma of the ovary: A clinicopathologic study of 30 cases. Am J Surg Pathol. 2018;42(4):534–544. doi: 10.1097/PAS.0000000000001016Assem H., Rambau P.F., Lee S., et al. High-grade endometrioid carcinoma of the ovary: A clinicopathologic study of 30 cases // Am J Surg Pathol. 2018. Vol. 42, N. 4. P. 534–544. doi: 10.1097/PAS.0000000000001016Woodbeck R, Kelemen LE, Köbel M. Ovarian endometrioid carcinoma misdiagnosed as mucinous carcinoma: An underrecognized problem. Int J Gynecol Pathol. 2019;38(6):568–575. doi: 10.1097/PGP.0000000000000564Woodbeck R., Kelemen L.E., Köbel M. Ovarian endometrioid carcinoma misdiagnosed as mucinous carcinoma: An underrecognized problem // Int J Gynecol Pathol. 2019. Vol. 38, N. 6. P. 568–575. doi: 10.1097/PGP.0000000000000564Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, de Ladurantaye M, Lee S, Leung S, Goode EL, Ramus SJ, Carlson JW, Li X, Ewanowich CA, Kelemen LE, Vanderhyden B, Provencher D, Huntsman D, Lee CH, Gilks CB, Mes Masson AM. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430–441. doi: 10.1097/PGP.0000000000000274Köbel M., Rahimi K., Rambau P.F., et al. An immunohistochemical algorithm for ovarian carcinoma typing // Int J Gynecol Pathol. 2016. Vol. 35, N. 5. P. 430–441. doi: 10.1097/PGP.0000000000000274Nagy A, Vitásková E, Černíková L, Křivda V, Jiřincová H, Sedlák K, Horníčková J, Havlíčková M. Evaluation of TaqMan qPCR system integrating two identically labelled hydrolysis probes in single assay. Sci Rep. 2017;7:41392. doi: 10.1038/srep41392Nagy A., Vitásková E., Černíková L., et al. Evaluation of TaqMan qPCR system integrating two identically labelled hydrolysis probes in single assay // Sci Rep. 2017. Vol. 7. P. 41392. doi: 10.1038/srep41392Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108. doi: 10.1038/nprot.2008.73Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method // Nat Protoc. 2008. Vol. 3, N. 6. P. 1101–1108. doi: 10.1038/nprot.2008.73Song Y, Yuan M, Wang G. Update value and clinical application of MUC16 (cancer antigen 125). Expert Opin Ther Targets. 2023;27(8):745–756. doi: 10.1080/14728222.2023.2248376Song Y., Yuan M., Wang G. Update value and clinical application of MUC16 (cancer antigen 125) // Expert Opin Ther Targets. 2023. Vol. 27, N. 8. P. 745–756. doi: 10.1080/14728222.2023.2248376Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, Bhaskaran N, Souchelnytskyi S, Hellman U, Filonenko V, Jungbluth AA, Odunsi K, Lloyd KO, Old LJ, Ritter G. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008;8:3. PMID: 18251464Yin B.W., Kiyamova R., Chua R., et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas // Cancer Immun. 2008. Vol. 8. P. 3. PMID: 18251464Peña-Blanco A, García-Sáez AJ. Bax, Bak and beyond — mitochondrial performance in apoptosis. FEBS J. 2018;285(3):416–431. doi: 10.1111/febs.14186Peña-Blanco A., García-Sáez A.J. Bax, Bak and beyond — mitochondrial performance in apoptosis // FEBS J. 2018. Vol. 285, N. 3. P. 416–431. doi: 10.1111/febs.14186Sun X, Huang S, Wang X, Zhang X, Wang X. CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. Oncotarget. 2018;9(44):27574–27584. doi: 10.18632/oncotarget.24164Sun X., Huang S., Wang X., et al. CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia // Oncotarget. 2018. Vol. 9, N. 44. P. 27574–27584. doi: 10.18632/oncotarget.24164Morana O, Wood W, Gregory CD. The apoptosis paradox in cancer. Int J Mol Sci. 2022;23(3):1328. doi: 10.3390/ijms23031328Morana O., Wood W., Gregory C.D. The apoptosis paradox in cancer // Int J Mol Sci. 2022. Vol. 23, N. 3. P. 1328. doi: 10.3390/ijms23031328Behuria HG, Dash S, Sahu SK. Phospholipid scramblases: Role in cancer progression and anticancer therapeutics. Front Genet. 2022;13:875894. doi: 10.3389/fgene.2022.875894Behuria H.G., Dash S., Sahu S.K. Phospholipid scramblases: Role in cancer progression and anticancer therapeutics // Front Genet. 2022. Vol. 13. P. 875894. doi: 10.3389/fgene.2022.875894Wei H, Wang H, Wang G, Qu L, Jiang L, Dai S, Chen X, Zhang Y, Chen Z, Li Y, Guo M, Chen Y. Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity. Nat Commun. 2023;14(1):4300. doi: 10.1038/s41467-023-40087-2Wei H., Wang H., Wang G., et al. Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity // Nat Commun. 2023. Vol. 14, N. 1. P. 4300. doi: 10.1038/s41467-023-40087-2Abdel-Maksoud MA, Ullah S, Nadeem A, Shaikh A, Zia MK, Zakri AM, Almanaa TN, Alfuraydi AA, Mubarak A, Hameed Y. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis. Am J Transl Res. 2024;16(1):63–74. doi: 10.62347/TWOY1681Abdel-Maksoud M.A., Ullah S., Nadeem A., et al. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis // Am J Transl Res. 2024. Vol. 16, N. 1. P. 63–74. doi: 10.62347/TWOY1681Zhang XY, Hong LL, Ling ZQ. MUC16: Clinical targets with great potential. Clin Exp Med. 2024;24(1):101. doi: 10.1007/s10238-024-01365-5Zhang X.Y., Hong L.L., Ling Z.Q. MUC16: Clinical targets with great potential // Clin Exp Med. 2024. Vol. 24, N. 1. P. 101. doi: 10.1007/s10238-024-01365-5Perez BH, Gipson IK. Focus on molecules. Exp Eye Res. 2008;87(5):400–401. doi: 10.1016/j.exer.2007.12.008Perez B.H., Gipson I.K. Focus on molecules // Exp Eye Res. 2008. Vol. 87, N. 5. P. 400–401. doi: 10.1016/j.exer.2007.12.008Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, Junker WM, Jain M, Ponnusamy MP, Batra SK. MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets. 2018;22(8):675–686. doi: 10.1080/14728222.2018.1498845Aithal A., Rauth S., Kshirsagar P., et al. MUC16 as a novel target for cancer therapy // Expert Opin Ther Targets. 2018. Vol. 22, N. 8. P. 675–686. doi: 10.1080/14728222.2018.1498845Gandhi T, Zubair M, Bhatt H. Cancer antigen 125. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562245/ Accessed: Mar 12, 2024.Gandhi T., Zubair M., Bhatt H. Cancer antigen 125. Treasure Island (FL): StatPearls Publishing, 2024. Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK562245/ Дата обращения: 12.03.2024.Lankry D, Rovis TL, Jonjic S, Mandelboim O. The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. Eur J Immunol. 2013;43(8):2151–2161. doi: 10.1002/eji.201343433Lankry D., Rovis T.L., Jonjic S., Mandelboim O. The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells // Eur J Immunol. 2013. Vol. 43, N. 8. P. 2151–2161. doi: 10.1002/eji.201343433Xu ZJ, Jin Y, Zhang XL, Xia PH, Wen XM, Ma JC, Lin J, Qian J. Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. Cancer Med. 2023;12(1):789–807. doi: 10.1002/cam4.4905Xu Z.J., Jin Y., Zhang X.L., et al. Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia // Cancer Med. 2023. Vol. 12, N. 1. P. 789–807. doi: 10.1002/cam4.4905Chen Y, Huang Y, Li Q, Luo Z, Zhang Z, Huang H, Sun J, Zhang L, Sun R, Bain DJ, Conway JF, Lu B, Li S. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023;18(2):193–204. doi: 10.1038/s41565-022-01266-2Chen Y., Huang Y., Li Q., et al. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy // Nat Nanotechnol. 2023. Vol. 18, N. 2. P. 193–204. doi: 10.1038/s41565-022-01266-2Murer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004;447(5):763–767. doi: 10.1007/s00424-003-1072-5Murer H., Forster I., Biber J. The sodium phosphate cotransporter family SLC34 // Pflugers Arch. 2004. Vol. 447, N. 5. P. 763–767. doi: 10.1007/s00424-003-1072-5Forster IC, Hernando N, Biber J, Murer H. Proximal tubular handling of phosphate: A molecular perspective. Kidney Int. 2006;70(9):1548–1559. doi: 10.1038/sj.ki.5001813Forster I.C., Hernando N., Biber J., Murer H. Proximal tubular handling of phosphate: A molecular perspective // Kidney Int. 2006. Vol. 70, N. 9. P. 1548–1559. doi: 10.1038/sj.ki.5001813Levi M, Gratton E, Forster IC, Hernando N, Wagner CA, Biber J, Sorribas V, Murer H. Mechanisms of phosphate transport. Nat Rev Nephrol. 2019;15(8):482–500. doi: 10.1038/s41581-019-0159-yLevi M., Gratton E., Forster I.C., et al. Mechanisms of phosphate transport // Nat Rev Nephrol. 2019. Vol. 15, N. 8. P. 482–500. doi: 10.1038/s41581-019-0159-yForster IC, Hernando N, Biber J, Murer H. Phosphate transporters of the SLC20 and SLC34 families. Mol Aspects Med. 2013;34(2–3):386–395. doi: 10.1016/j.mam.2012.07.007Forster I.C., Hernando N., Biber J., Murer H. Phosphate transporters of the SLC20 and SLC34 families // Mol Aspects Med. 2013. Vol. 34, N. 2–3. P. 386–395. doi: 10.1016/j.mam.2012.07.007Jönsson ÅLM, Bendstrup E, Mogensen S, Kopras EJ, McCormack FX, Campo I, Mariani F, Escribano-Montaner A, Holm AM, Martinez-Colls MDM, Pintos-Morell G, Taillé C, Crestani B, Hilberg O, Hvarregaard Christensen J, Simonsen U. Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. Eur Respir J. 2020;55(2):1900806. doi: 10.1183/13993003.00806-2019Jönsson Å.L.M., Bendstrup E., Mogensen S., et al. Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis // European Respiratory Journal. 2020. Vol. 55, N. 2. P. 1900806. doi: 10.1183/13993003.00806-2019Patti M, Fenollar-Ferrer C, Werner A, Forrest LR, Forster IC. Cation interactions and membrane potential induce conformational changes in NaPi-IIb. Biophys J. 2016;111(5):973–988. doi: 10.1016/j.bpj.2016.07.025Patti M., Fenollar-Ferrer C., Werner A., et al. Cation interactions and membrane potential induce conformational changes in NaPi-IIb // Biophys J. 2016. Vol. 111, N. 5. P. 973–988. doi: 10.1016/j.bpj.2016.07.025Bulatova L, Savenkova D, Nurgalieva A, Reshetnikova D, Timonina A, Skripova V, Bogdanov M, Kiyamova R. Toward a topology-based therapeutic design of membrane proteins: Validation of NaPi2b topology in live ovarian cancer cells. Front Mol Biosci. 2022;9:895911. doi: 10.3389/fmolb.2022.895911Bulatova L., Savenkova D., Nurgalieva A., et al. Toward a topology-based therapeutic design of membrane proteins: Validation of NaPi2b topology in live ovarian cancer cells // Front Mol Biosci. 2022. Vol. 9. P. 895911. doi: 10.3389/fmolb.2022.895911Soares IC, Simões K, de Souza JE, Okamoto OK, Wakamatsu A, Tuma M, Ritter G, Alves VA. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35. Appl Immunohistochem Mol Morphol. 2012;20(2):165–172. doi: 10.1097/pai.0b013e318228e232Soares I.C., Simões K., de Souza J.E., et al. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35 // Appl Immunohistochem Mol Morphol. 2012. Vol. 20, N. 2. P. 165–172. doi: 10.1097/pai.0b013e318228e232Kiyamova R, Minigulova LF, Skripova V, Nurgalieva A, Reshetnikova D, Savinska L, Filonenko V, Bogdanov M. 34P N-glycosylation status of membrane phosphate transporter NaPi2b is crucial for its epitope recognition by monoclonal antibody in tumour cells. Annals of Oncology. 2020;31:S1227–S1228. doi: 10.1016/j.annonc.2020.08.2193Kiyamova R., Minigulova L.F., Skripova V., et al. 34P N-glycosylation status of membrane phosphate transporter NaPi2b is crucial for its epitope recognition by monoclonal antibody in tumour cells // Annals of Oncology. 2020. Vol. 31. P. S1227–S1228. doi: 10.1016/j.annonc.2020.08.2193Bulatova LF, Skripova V, Nurgalieva A, Reshetnikova D, Savenkova DV, Timonina A, Bogdanov MV, Kiyamova RG. 26P Structurally constrained tumor-specific epitope within the largest extracellular domain of sodium-dependent phosphate transporter NaPi2b. Annals of Oncology. 2021;32:S368–S369. doi: 10.1016/j.annonc.2021.08.304Bulatova L.F., Skripova V., Nurgalieva A., et al. 26P Structurally constrained tumor-specific epitope within the largest extracellular domain of sodium-dependent phosphate transporter NaPi2b // Annals of Oncology. 2021. Vol. 32. P. S368–S369. doi: 10.1016/j.annonc.2021.08.304Zhang Z, Ye S, Zhang M, Wu J, Yan H, Li X, He J. High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients. Tumour Biol. 2017;39(7):1010428317720212. doi: 10.1177/1010428317720212Zhang Z., Ye S., Zhang M., et al. High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients // Tumour Biol. 2017. Vol. 39, N. 7. P. 1010428317720212. doi: 10.1177/1010428317720212Levan K, Mehryar M, Mateoiu C, Albertsson P, Bäck T, Sundfeldt K. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer. 2017;17:303. doi: 10.1186/s12885-017-3289-2Levan K., Mehryar M., Mateoiu C., et al. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b // BMC Cancer. 2017. Vol. 17. P. 303. doi: 10.1186/s12885-017-3289-2